418 related articles for article (PubMed ID: 18668203)
1. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant.
Casella CR; Mitchell TC
Cell Mol Life Sci; 2008 Oct; 65(20):3231-40. PubMed ID: 18668203
[TBL] [Abstract][Full Text] [Related]
2. Monophosphoryl lipid A and endotoxin tolerance.
Hamilton-Davies C; Webb AR
Crit Care Med; 1995 Oct; 23(10):1789-90. PubMed ID: 7587249
[No Abstract] [Full Text] [Related]
3. Characterization of a nontoxic monophosphoryl lipid A.
Johnson AG; Tomai M; Solem L; Beck L; Ribi E
Rev Infect Dis; 1987; 9 Suppl 5():S512-6. PubMed ID: 3317747
[TBL] [Abstract][Full Text] [Related]
4. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents.
Baldridge JR; McGowan P; Evans JT; Cluff C; Mossman S; Johnson D; Persing D
Expert Opin Biol Ther; 2004 Jul; 4(7):1129-38. PubMed ID: 15268679
[TBL] [Abstract][Full Text] [Related]
5. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.
Mata-Haro V; Cekic C; Martin M; Chilton PM; Casella CR; Mitchell TC
Science; 2007 Jun; 316(5831):1628-32. PubMed ID: 17569868
[TBL] [Abstract][Full Text] [Related]
6. Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery.
Gregg KA; Harberts E; Gardner FM; Pelletier MR; Cayatte C; Yu L; McCarthy MP; Marshall JD; Ernst RK
mBio; 2017 May; 8(3):. PubMed ID: 28487429
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
Rostamian M; Niknam HM
Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
[TBL] [Abstract][Full Text] [Related]
8. Immunopharmacology of lipid A mimetics.
Bowen WS; Gandhapudi SK; Kolb JP; Mitchell TC
Adv Pharmacol; 2013; 66():81-128. PubMed ID: 23433456
[TBL] [Abstract][Full Text] [Related]
9. Engineering Escherichia coli for constitutive production of monophosphoryl lipid A vaccine adjuvant.
Jin H; Ji Y; An J; Ha DH; Lee YR; Kim HJ; Lee CG; Jeong W; Kwon IC; Yang EG; Kim KH; Lee C; Chung HS
Biotechnol Bioeng; 2024 Mar; 121(3):1144-1162. PubMed ID: 38184812
[TBL] [Abstract][Full Text] [Related]
10. Taking toll: lipid A mimetics as adjuvants and immunomodulators.
Persing DH; Coler RN; Lacy MJ; Johnson DA; Baldridge JR; Hershberg RM; Reed SG
Trends Microbiol; 2002; 10(10 Suppl):S32-7. PubMed ID: 12377566
[TBL] [Abstract][Full Text] [Related]
11. Endothelial cell tolerance to lipopolysaccharide challenge is induced by monophosphoryl lipid A.
Stark RJ; Choi H; Koch SR; Fensterheim BA; Lamb FS; Sherwood ER
Clin Sci (Lond); 2016 Mar; 130(6):451-61. PubMed ID: 26669797
[TBL] [Abstract][Full Text] [Related]
12. Adjuvants for vaccines to drugs of abuse and addiction.
Alving CR; Matyas GR; Torres O; Jalah R; Beck Z
Vaccine; 2014 Sep; 32(42):5382-9. PubMed ID: 25111169
[TBL] [Abstract][Full Text] [Related]
13. Lipid A-Mediated Bacterial-Host Chemical Ecology: Synthetic Research of Bacterial Lipid As and Their Development as Adjuvants.
Shimoyama A; Fukase K
Molecules; 2021 Oct; 26(20):. PubMed ID: 34684874
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.
Didierlaurent AM; Collignon C; Bourguignon P; Wouters S; Fierens K; Fochesato M; Dendouga N; Langlet C; Malissen B; Lambrecht BN; Garçon N; Van Mechelen M; Morel S
J Immunol; 2014 Aug; 193(4):1920-30. PubMed ID: 25024381
[TBL] [Abstract][Full Text] [Related]
15. Correlates of GLA family adjuvants' activities.
Reed SG; Carter D; Casper C; Duthie MS; Fox CB
Semin Immunol; 2018 Oct; 39():22-29. PubMed ID: 30366662
[TBL] [Abstract][Full Text] [Related]
16. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondii.
Song P; He S; Zhou A; Lv G; Guo J; Zhou J; Han Y; Zhou H; Hao Z; Cong H
BMC Infect Dis; 2017 Jan; 17(1):19. PubMed ID: 28056837
[TBL] [Abstract][Full Text] [Related]
18. Early-phase endotoxin tolerance: induction by a detoxified lipid A derivative, monophosphoryl lipid A.
Madonna GS; Peterson JE; Ribi EE; Vogel SN
Infect Immun; 1986 Apr; 52(1):6-11. PubMed ID: 3514464
[TBL] [Abstract][Full Text] [Related]
19. MPL Adjuvant Contains Competitive Antagonists of Human TLR4.
Wang YQ; Bazin-Lee H; Evans JT; Casella CR; Mitchell TC
Front Immunol; 2020; 11():577823. PubMed ID: 33178204
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling.
Gavin AL; Hoebe K; Duong B; Ota T; Martin C; Beutler B; Nemazee D
Science; 2006 Dec; 314(5807):1936-8. PubMed ID: 17185603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
